BiotechTube

Lidocaine 1.8% + Placebo

ApprovedCompleted
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Carpal Tunnel Syndrome

Conditions

Carpal Tunnel Syndrome

Trial Timeline

Feb 24, 2020 → May 7, 2023

NCT ID
NCT04245371

About Lidocaine 1.8% + Placebo

Lidocaine 1.8% + Placebo is a approved stage product being developed by Scilex Holding for Carpal Tunnel Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT04245371. Target conditions include Carpal Tunnel Syndrome.

Hype Score Breakdown

Clinical
30
Activity
20
Company
2
Novelty
10
Community
12

Clinical Trials (1)

NCT IDPhaseStatus
NCT04245371ApprovedCompleted

Competing Products

1 competing product in Carpal Tunnel Syndrome

See all competitors
ProductCompanyStageHype Score
GabapentinPfizerPhase 3
76

Other Products from Scilex Holding

SP-102 + PlaceboPhase 3
69
SP-103 + PlaceboPhase 2
44
SP-102Phase 2
44
ZTlido (Lidocaine Topical System) 1.8% + Salonpas (Lidocaine Patch 4%) + Aspercreme (Lidocaine Patch 4%) + IcyHot (Lidocaine 4% + Menthol 1% Patch)Phase 1
25
lidocaine topical system 1.8% + lidocaine patch 5%Phase 1
25